Regeneron Pharmaceuticals

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data - Regeneron Pharmaceuticals (öffnet in neuem Tab)

  Benzinga · 02.10.2026

• This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking (öffnet in neuem Tab)

  02.10.2026

• Regeneron Pharmaceuticals' (REGN) Sector Perform Rating Reaffirmed at Royal Bank Of Canada (öffnet in neuem Tab)

  MarketBeat · 02.10.2026

• A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $770 to $930 (öffnet in neuem Tab)

  Moomoo · 02.10.2026

• 
  Sanofi, Regeneron Expand Immunology Alliance With New Antibodies (öffnet in neuem Tab)

  02.10.2026

• 
  Sanofi pays Regeneron up to $8B to expand immunology alliance (öffnet in neuem Tab)

  02.10.2026

• Regeneron Phase II trial confirms trevogrumab halves muscle loss (öffnet in neuem Tab)

  The Pharma Letter · 02.10.2026

• Friday Five: Sanofi and Regeneron (re)partner up in the face of Dupixent's patent cliff, AstraZeneca invests $2B in Summit, Lilly delivers more weight loss wins…and more (öffnet in neuem Tab)

  FirstWord Pharma · 02.10.2026

• Regeneron (REGN) Stock May Be Underpriced Despite Its $1b Alliance Expansion (öffnet in neuem Tab)

  Simply Wall Street · 01.10.2026

• Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks (öffnet in neuem Tab)

  01.10.2026

• Why Regeneron (REGN) Stock Is Trading Lower Today (öffnet in neuem Tab)

  01.10.2026

• OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD (öffnet in neuem Tab)

  01.10.2026

• Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day (öffnet in neuem Tab)

  MarketWatch · 01.10.2026

• Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion (öffnet in neuem Tab)

  MarketBeat · 01.10.2026

• Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent (öffnet in neuem Tab)

  MedCity News · 01.10.2026

• Baird reiterates Regeneron stock rating on Sanofi collaboration By Investing.com (öffnet in neuem Tab)

  Investing.com India · 01.10.2026

• Sanofi To Pay Regeneron Up To $8B In Immunology Alliance (öffnet in neuem Tab)

  Law360 · 01.10.2026

• Sanofi And Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Billion (öffnet in neuem Tab)

  pulse2.com · 01.10.2026

• Regeneron Pharmaceuticals (NDQ:REGN): Is This Dark Horse The TSMC Of The Pharmaceutical Sector? (öffnet in neuem Tab)

  Stocks Down Under · 01.10.2026

• Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00 (öffnet in neuem Tab)

  MarketBeat · 01.10.2026

• Sanofi Commits Up to $8 Billion to Expand Regeneron Alliance on Next-Gen Antibodies (öffnet in neuem Tab)

  finance.biggo.com · 01.10.2026

• Regeneron stock after-hours at EUR 660.45: minus 1.31 percent versus prior close (öffnet in neuem Tab)

  AD HOC NEWS · 01.10.2026

• Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Tr (öffnet in neuem Tab)

  GuruFocus · 01.10.2026

• Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN) (öffnet in neuem Tab)

  Seeking Alpha · 01.10.2026

• Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Tri (öffnet in neuem Tab)

  GuruFocus · 01.10.2026

• Regeneron posts trial data for ovarian cancer therapy (REGN:NASDAQ) (öffnet in neuem Tab)

  Seeking Alpha · 01.10.2026

• Regeneron Pharmaceuticals (REGN) Unveils Positive Phase 2 COURAG (öffnet in neuem Tab)

  GuruFocus · 01.10.2026

• Sanofi and Regeneron expand global alliance (öffnet in neuem Tab)

  The Pharma Letter · 01.10.2026

• Regeneron, Sanofi Expand Alliance with $1 Billion Upfront, 4 Antibodies (öffnet in neuem Tab)

  BioPharm International · 01.10.2026

• Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients (öffnet in neuem Tab)

  TradingView · 01.10.2026